1. Home
  2. JAGX vs ONCO Comparison

JAGX vs ONCO Comparison

Compare JAGX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$1.18

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$2.01

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JAGX
ONCO
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
4.3M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
JAGX
ONCO
Price
$1.18
$2.01
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$60.00
N/A
AVG Volume (30 Days)
380.3K
37.9K
Earning Date
11-17-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,785,000.00
$1,223,751.00
Revenue This Year
$22.41
N/A
Revenue Next Year
$30.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.45
N/A
52 Week Low
$1.00
$2.10
52 Week High
$33.25
$179.35

Technical Indicators

Market Signals
Indicator
JAGX
ONCO
Relative Strength Index (RSI) 41.39 35.11
Support Level $1.05 $2.53
Resistance Level $1.36 $3.22
Average True Range (ATR) 0.16 0.33
MACD 0.04 -0.03
Stochastic Oscillator 38.00 4.17

Price Performance

Historical Comparison
JAGX
ONCO

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: